Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-TCRc4 T Cells for High-Risk AML
NCT02770820Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of JTCR016 in acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Nov 2017; status: terminated.
02
Drugs
JTCR016
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02770820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770820.